Considering the important role of IL-11/STAT3 signaling pathway in tumor progression and metastasis, therapeutic options using direct STAT3 inhibitors or upstream inhibitors might be used for the treatment of ccRCC in the future. The gene discussed is STAT3; the disease is nonpapillary renal cell carcinoma.